Albany Molecular Research, Inc. (AMRI) Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. reduced its position in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) by 0.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 91,110 shares of the biotechnology company’s stock after selling 189 shares during the period. Bessemer Group Inc.’s holdings in Albany Molecular Research were worth $1,977,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp boosted its position in Albany Molecular Research by 7.2% in the fourth quarter. State Street Corp now owns 512,819 shares of the biotechnology company’s stock worth $9,623,000 after buying an additional 34,448 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in Albany Molecular Research by 4.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 11,990 shares of the biotechnology company’s stock worth $225,000 after buying an additional 550 shares during the last quarter. Teachers Advisors LLC boosted its position in Albany Molecular Research by 0.5% in the fourth quarter. Teachers Advisors LLC now owns 41,916 shares of the biotechnology company’s stock worth $786,000 after buying an additional 198 shares during the last quarter. Atria Investments LLC boosted its position in Albany Molecular Research by 11.2% in the first quarter. Atria Investments LLC now owns 17,670 shares of the biotechnology company’s stock worth $248,000 after buying an additional 1,782 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its position in Albany Molecular Research by 79.2% in the first quarter. Fisher Asset Management LLC now owns 144,417 shares of the biotechnology company’s stock worth $2,026,000 after buying an additional 63,828 shares during the last quarter. Hedge funds and other institutional investors own 73.43% of the company’s stock.

Shares of Albany Molecular Research, Inc. (NASDAQ AMRI) opened at 21.75 on Friday. The stock’s market capitalization is $904.89 million. Albany Molecular Research, Inc. has a 52 week low of $13.01 and a 52 week high of $22.17. The company’s 50 day moving average is $21.70 and its 200-day moving average is $18.05.

Albany Molecular Research (NASDAQ:AMRI) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The firm had revenue of $163.80 million during the quarter, compared to analyst estimates of $161.43 million. Albany Molecular Research had a negative net margin of 11.26% and a positive return on equity of 11.97%. The business’s revenue for the quarter was up 55.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.07 earnings per share. On average, equities analysts predict that Albany Molecular Research, Inc. will post $1.13 earnings per share for the current year.

WARNING: “Albany Molecular Research, Inc. (AMRI) Shares Sold by Bessemer Group Inc.” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2801901/albany-molecular-research-inc-amri-shares-sold-by-bessemer-group-inc.html.

AMRI has been the topic of a number of research analyst reports. Morgan Stanley cut shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 target price on the stock. in a research note on Thursday, May 11th. They noted that the move was a valuation call. William Blair reiterated an “outperform” rating on shares of Albany Molecular Research in a research note on Tuesday, May 23rd. J P Morgan Chase & Co cut shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 8th. First Analysis cut shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research note on Monday, June 12th. Finally, BidaskClub cut shares of Albany Molecular Research from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. Albany Molecular Research has a consensus rating of “Hold” and an average price target of $18.00.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research, Inc. (NASDAQ:AMRI).

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.